药剂师管理的糖尿病护理和A1C的变化:一项回顾性匹配队列研究

IF 1.5 Q4 PHARMACOLOGY & PHARMACY Journal of the American College of Clinical Pharmacy : JACCP Pub Date : 2024-12-05 DOI:10.1002/jac5.2058
Nicholas C. Meyer Pharm.D., Fatme Younes Pharm.D., Carlina J. Grindeland Pharm.D., Monte L. Roemmich Pharm.D., Douglas W. Gugel-Bryant Pharm.D.
{"title":"药剂师管理的糖尿病护理和A1C的变化:一项回顾性匹配队列研究","authors":"Nicholas C. Meyer Pharm.D.,&nbsp;Fatme Younes Pharm.D.,&nbsp;Carlina J. Grindeland Pharm.D.,&nbsp;Monte L. Roemmich Pharm.D.,&nbsp;Douglas W. Gugel-Bryant Pharm.D.","doi":"10.1002/jac5.2058","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Studies have demonstrated the positive impact of pharmacist-managed diabetes care (PMDC) on hemoglobin A1C (A1C) reduction from baseline, but data comparing the pharmacist's impact on usual medical care (UMC) are less robust.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This study compared the A1C reduction in patients with diabetes enrolled in PMDC plus UMC (PMDC + UMC) with similar patients receiving UMC independent of clinical pharmacy services.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a retrospective, matched cohort study conducted at a large, not-for-profit healthcare system in North Dakota. Patients with diabetes who received care from an ambulatory care pharmacist in addition to UMC between July 2018 and June 2020 were included in the PMDC+UMC cohort. The comparator cohort included propensity-matched patients solely receiving UMC during the same period. The primary endpoint was the mean change in A1C at 12 months in both cohorts. The secondary endpoint was the percentage of patients in each cohort achieving an A1C &lt;7% at 12 months. Normally distributed continuous variables were analyzed using the Wilcoxon rank sum test. Categorical data were analyzed using Chi-square tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 158 patients managed by a pharmacist met the inclusion criteria for the study. A matched cohort of 158 practitioner-managed patients was used for comparison. Pharmacist-managed patients achieved a greater mean reduction in A1C (−1.70%) at 12 months compared with those managed by practitioners only (−1.31%), a between-means difference of −0.39% (<i>p</i> = 0.0073). More patients managed by pharmacists (24.6%) reached an A1C of &lt;7% compared with patients receiving UMC only (22.8%); however, the difference was not statistically significant.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Incorporation of PMDC for patients with diabetes is associated with a greater improvement in A1C at 12 months compared with UMC alone. Although not statistically significant, more patients referred to PMDC reached an A1C of &lt;7%. Implementation of similar PMDC programs may help more patients reach their glycemic goals.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 1","pages":"28-33"},"PeriodicalIF":1.5000,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacist-managed diabetes care and change in A1C: A retrospective matched cohort study\",\"authors\":\"Nicholas C. Meyer Pharm.D.,&nbsp;Fatme Younes Pharm.D.,&nbsp;Carlina J. Grindeland Pharm.D.,&nbsp;Monte L. Roemmich Pharm.D.,&nbsp;Douglas W. Gugel-Bryant Pharm.D.\",\"doi\":\"10.1002/jac5.2058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Studies have demonstrated the positive impact of pharmacist-managed diabetes care (PMDC) on hemoglobin A1C (A1C) reduction from baseline, but data comparing the pharmacist's impact on usual medical care (UMC) are less robust.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>This study compared the A1C reduction in patients with diabetes enrolled in PMDC plus UMC (PMDC + UMC) with similar patients receiving UMC independent of clinical pharmacy services.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This was a retrospective, matched cohort study conducted at a large, not-for-profit healthcare system in North Dakota. Patients with diabetes who received care from an ambulatory care pharmacist in addition to UMC between July 2018 and June 2020 were included in the PMDC+UMC cohort. The comparator cohort included propensity-matched patients solely receiving UMC during the same period. The primary endpoint was the mean change in A1C at 12 months in both cohorts. The secondary endpoint was the percentage of patients in each cohort achieving an A1C &lt;7% at 12 months. Normally distributed continuous variables were analyzed using the Wilcoxon rank sum test. Categorical data were analyzed using Chi-square tests.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In total, 158 patients managed by a pharmacist met the inclusion criteria for the study. A matched cohort of 158 practitioner-managed patients was used for comparison. Pharmacist-managed patients achieved a greater mean reduction in A1C (−1.70%) at 12 months compared with those managed by practitioners only (−1.31%), a between-means difference of −0.39% (<i>p</i> = 0.0073). More patients managed by pharmacists (24.6%) reached an A1C of &lt;7% compared with patients receiving UMC only (22.8%); however, the difference was not statistically significant.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Incorporation of PMDC for patients with diabetes is associated with a greater improvement in A1C at 12 months compared with UMC alone. Although not statistically significant, more patients referred to PMDC reached an A1C of &lt;7%. Implementation of similar PMDC programs may help more patients reach their glycemic goals.</p>\\n </section>\\n </div>\",\"PeriodicalId\":73966,\"journal\":{\"name\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"volume\":\"8 1\",\"pages\":\"28-33\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2058\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.2058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

研究表明,药剂师管理的糖尿病护理(PMDC)对血红蛋白A1C (A1C)从基线降低的积极影响,但比较药剂师对常规医疗护理(UMC)影响的数据不太可靠。本研究比较了参加PMDC + UMC (PMDC + UMC)的糖尿病患者与独立于临床药学服务接受UMC的类似患者的A1C降低情况。方法:这是一项回顾性的、匹配的队列研究,在北达科他州的一个大型非营利性医疗保健系统中进行。2018年7月至2020年6月期间除UMC外接受门诊护理药剂师护理的糖尿病患者被纳入PMDC+UMC队列。比较队列包括在同一时期单独接受UMC的倾向匹配的患者。主要终点是两组患者12个月时A1C的平均变化。次要终点是每组患者在12个月时A1C达到7%的百分比。使用Wilcoxon秩和检验分析正态分布的连续变量。分类资料采用卡方检验进行分析。结果共有158名由药剂师管理的患者符合研究的纳入标准。158名由医生管理的患者组成的匹配队列用于比较。与仅由执业医师管理的患者(- 1.31%)相比,药剂师管理的患者在12个月时实现了更大的A1C平均降低(- 1.70%),平均差为- 0.39% (p = 0.0073)。由药师管理的患者(24.6%)的糖化血红蛋白(A1C)达到7%,而仅接受UMC管理的患者(22.8%)达到7%;然而,差异无统计学意义。结论:与单用UMC相比,合并PMDC治疗糖尿病患者12个月时A1C的改善更大。虽然没有统计学意义,但更多的PMDC患者的A1C达到了7%。实施类似的PMDC计划可能会帮助更多的患者达到他们的血糖目标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Pharmacist-managed diabetes care and change in A1C: A retrospective matched cohort study

Introduction

Studies have demonstrated the positive impact of pharmacist-managed diabetes care (PMDC) on hemoglobin A1C (A1C) reduction from baseline, but data comparing the pharmacist's impact on usual medical care (UMC) are less robust.

Objectives

This study compared the A1C reduction in patients with diabetes enrolled in PMDC plus UMC (PMDC + UMC) with similar patients receiving UMC independent of clinical pharmacy services.

Methods

This was a retrospective, matched cohort study conducted at a large, not-for-profit healthcare system in North Dakota. Patients with diabetes who received care from an ambulatory care pharmacist in addition to UMC between July 2018 and June 2020 were included in the PMDC+UMC cohort. The comparator cohort included propensity-matched patients solely receiving UMC during the same period. The primary endpoint was the mean change in A1C at 12 months in both cohorts. The secondary endpoint was the percentage of patients in each cohort achieving an A1C <7% at 12 months. Normally distributed continuous variables were analyzed using the Wilcoxon rank sum test. Categorical data were analyzed using Chi-square tests.

Results

In total, 158 patients managed by a pharmacist met the inclusion criteria for the study. A matched cohort of 158 practitioner-managed patients was used for comparison. Pharmacist-managed patients achieved a greater mean reduction in A1C (−1.70%) at 12 months compared with those managed by practitioners only (−1.31%), a between-means difference of −0.39% (p = 0.0073). More patients managed by pharmacists (24.6%) reached an A1C of <7% compared with patients receiving UMC only (22.8%); however, the difference was not statistically significant.

Conclusion

Incorporation of PMDC for patients with diabetes is associated with a greater improvement in A1C at 12 months compared with UMC alone. Although not statistically significant, more patients referred to PMDC reached an A1C of <7%. Implementation of similar PMDC programs may help more patients reach their glycemic goals.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
期刊最新文献
Issue Information 2026 ACCP Virtual Poster Symposium May 19 & 20, 2026 Prescribing Caution: A Critique of OpenEvidence to Answer Medication-Related Questions Human Dignity and Scientific Integrity: Using Artificial Intelligence in Scholarly Writing Case Series: Pediatric Vaccinations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1